U.S. lawmakers held a hearing Thursday to discuss a House draft bill that would require the tracking of medicines by lots, instead of tracing every drug unit as proposed in a Senate bill. Industry groups favor tracking by lots, saying that the technology needed to track individual saleable units is too costly, but the FDA favors the type of system outlined in the Senate bill. Strong national standards are essential to fight counterfeit medicines, according to Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research. The FDA will need regulatory power to enforce adherence to the requirements, Woodcock added.
Published in Brief: